Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk.
about
Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndromeBlood coagulation and the risk of atherothrombosis: a complex relationshipSystematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian PopulationAdipose tissue and adipokines: the association with and application of adipokines in obesityCCAAT/enhancer binding protein β in relation to ER stress, inflammation, and metabolic disturbancesInsulin and glucose play a role in foam cell formation and function.The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS)Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.Seabuckthorn Leaves Extract and Flavonoid Glycosides Extract from Seabuckthorn Leaves Ameliorates Adiposity, Hepatic Steatosis, Insulin Resistance, and Inflammation in Diet-Induced Obesity.4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic studyPlasminogen activator inhibitor type 1 gene polymorphism and sepsis.Transcriptome analysis of subcutaneous adipose tissues in beef cattle using 3' digital gene expression-tag profiling.Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditionsThe ternary complex factor Net regulates cell migration through inhibition of PAI-1 expressionMetabolic syndrome and cardiovascular risk.Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjectsMetabolic syndrome in the pediatric population: a short overviewHepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reportsHepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome.Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance.The clinical biochemistry of obesity.Adipose tissue and atherothrombosis.Circulatory syndrome: an evolution of the metabolic syndrome concept!Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease.Diabetic and metabolic programming: mechanisms altering the intrauterine milieuHyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissueInjury-induced insulin resistance in adipose tissueBehçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity.n3 PUFAs do not affect adipose tissue inflammation in overweight to moderately obese men and women.Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysisGrowth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone.Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.Adipokines and cardiovascular risk in Cushing's syndrome.Meta-review of protein network regulating obesity between validated obesity candidate genes in the white adipose tissue of high-fat diet-induced obese C57BL/6J mice.Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1.Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review.PAI-1 gain-of-function genotype, factors increasing PAI-1 levels, and airway obstruction: The GALA II Cohort.Metabolic syndrome: pathophysiology, management, and modulation by natural compounds.
P2860
Q24648112-3CB50C9C-6749-483C-A76C-4484C91F41F3Q24808644-78F388C4-17C4-461E-A3F0-20BB0A1B0CF0Q26774109-411AAB32-D00C-4D00-838A-0B03171A04CBQ26830052-80DF0B94-BB0F-4EAB-AD78-19FC58A3DE8CQ26864146-E190CEA3-EEEF-49B5-8850-D4104EF37B62Q30440798-F4D3B578-ACDE-4BFF-96C9-67AEA2CCD2A6Q33567573-959C92BC-4E3C-482C-A288-DDA825FE405DQ33580624-561ED1FF-ACE9-4607-8CD0-50174BAF8B43Q33851911-08086CA2-4088-4C2E-8E9D-D5F1CDF32BCFQ33919345-48E7D759-8AD1-4D46-A948-B136ABE5B0CFQ33990846-B95B7AD8-DC1A-4A88-B020-DBD61BE4DD8AQ33998446-4BD849D0-EF4C-41A3-95D3-A112D4E8FE74Q34217461-9C427C3A-3509-4501-85AD-D13A65EE4222Q34230893-3F2FE947-6175-4317-B444-DF200BEF9C59Q34606875-1B7F51FA-B34A-4172-AEDD-370503FDFEAEQ34722566-F5E9882B-E27E-44B9-BABE-CE40AD9922C8Q34985768-D04C016D-48D5-4579-A346-8C1FCBAFF0BAQ35225125-C2FEBCC2-486F-42F7-90A0-24CE4D5EBEDCQ35683994-C6F9CDF0-825E-4DDC-B38A-D3F756262323Q35686289-20EF21A7-F690-4565-8441-DB54247DB9D8Q35688843-3FD5AC79-3B30-4A79-ABEC-E28A6FF8276AQ35819237-70494E2C-0CB1-453A-8513-FAD507342763Q36030434-7841B08E-31B2-4161-9379-3E7F6E21E815Q36087928-26F947C9-7064-4859-9A8C-90183D0D0167Q36230826-C9FFD8A0-2CC1-4B51-B8F8-400A5C5E7030Q36429681-450C175C-B428-46D8-8FA2-7443779E7A16Q36578832-7CA7E58D-1015-47AE-8F3C-3B6B576F6A79Q36676216-55646099-86CF-471D-8311-F2827FA5E8AEQ36891665-100CA5A4-702A-4430-9A78-E394FC603D50Q37008018-B06CDE79-B45D-42C7-8F6D-1EBC1756D06FQ37185489-D365CA40-D547-4B6B-9DB4-6C0437D78E16Q37396676-4354F05A-5513-4F88-A55C-E3C89AE66089Q37472064-310DAB94-2142-460A-9B4E-4F4B82D91748Q37722931-05EFEBC4-4926-4C3B-BA02-DA25B28827B7Q37953199-A9BA4C21-B2A5-430F-9276-B7BCDFAE7D32Q38185432-E0CA32A3-8E05-45CA-A8EF-6F2514745F22Q38291637-CC68BFBE-ABB8-498D-BE97-553ECCF5C1A9Q38669053-01ADCDE9-E326-4E00-B495-CA8084C871AAQ38764253-0B076E41-3D55-41F5-9B12-CBFAB9872413Q39390402-70A2C3FD-7061-4A98-8DC2-9C87FD635AAE
P2860
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Plasminogen activator inhibito ...... resistance and vascular risk.
@ast
Plasminogen activator inhibito ...... resistance and vascular risk.
@en
type
label
Plasminogen activator inhibito ...... resistance and vascular risk.
@ast
Plasminogen activator inhibito ...... resistance and vascular risk.
@en
prefLabel
Plasminogen activator inhibito ...... resistance and vascular risk.
@ast
Plasminogen activator inhibito ...... resistance and vascular risk.
@en
P2093
P2860
P1476
Plasminogen activator inhibito ...... resistance and vascular risk.
@en
P2093
Juhan-Vague I
Morange PE
P2860
P304
P356
10.1046/J.1538-7836.2003.00279.X
P577
2003-07-01T00:00:00Z